En los Países Bajos, una mujer de 89 años con cáncer de médula ósea se ha convertido en la primera persona en morir confirmadamente por una reinfección de COVID-19, marcando un momento sombrío en la comprensión global de la inmunidad. Su historia —recuperación, quimioterapia, y una segunda infección devastadora— recuerda que la vulnerabilidad no desaparece con la primera batalla contra el virus. En un mundo donde apenas se han documentado 25 casos de reinfección, este caso singular obliga a la ciencia a preguntarse cuánto tiempo dura la protección y quiénes quedan expuestos cuando el cuerpo ya
First COVID-19 Reinfection Death Confirmed in 89-Year-Old Dutch Woman
An 89-year-old Dutch woman died from COVID-19 reinfection, complicated by her underlying bone marrow cancer and immunosuppression from chemotherapy.
This protection will not last a lifetime
Mark
Why does this one death matter so much when millions have died from COVID-19?
Mimi
Because it's the first time we've seen someone get infected twice and die from it. That changes what we need to worry about—not just the first infection, but whether you can get it again, and what that means for people who thought they were safe.
Mark
But she had cancer. Doesn't that make her an outlier?
Mimi
Yes and no. She's an outlier in that she died, but she's a window into what happens when your immune system can't fight back. Most of us will recover fine twice over. But if you're on chemotherapy, or immunosuppressed for any reason, the rules might be different.
Mark
The article says only 25 reinfections known worldwide. That's tiny.
Mimi
Exactly. Which is why scientists aren't panicking. But it also means we don't know the real number yet. This woman was tracked because she was hospitalized. How many people got reinfected mildly and never knew?
Mark
What worries you most about this?
Mimi
That antibodies disappear faster than we thought in some people. If that's true, natural immunity might not be the fortress we hoped it was. That matters for how we think about vaccines and boosters.
Mark
Will this change how we treat cancer patients during the pandemic?
Mimi
It should. Doctors will have to think harder about timing chemotherapy, protecting these patients from exposure, maybe even reconsidering when to start treatment. This woman's cancer and the virus collided at exactly the wrong moment.
Il Polso
- Una mujer de 89 años murió tras contraer COVID-19 por segunda vez, convirtiéndose en el primer caso confirmado de muerte por reinfección en el mundo.
- Su sistema inmunológico, ya debilitado por un raro cáncer de médula ósea, no generó anticuerpos duraderos tras la primera infección, dejándola completamente desprotegida.
- La reinfección llegó apenas dos meses después de su recuperación inicial, un intervalo alarmantemente corto que desafía las expectativas sobre la duración de la inmunidad natural.
- Los científicos debaten si este caso es una anomalía ligada a la inmunosupresión o una señal de advertencia más amplia sobre la fragilidad de la protección contra el virus.
- Con solo 25 reinfecciones documentadas globalmente, los expertos advierten que estos casos seguirán aumentando y que las vacunas deberán enfrentar la misma pregunta: ¿cuánto tiempo protegen realmente?
En los Países Bajos, una mujer de 89 años con cáncer de médula ósea se ha convertido en la primera persona en morir confirmadamente por una reinfección de COVID-19, marcando un momento sombrío en la comprensión global de la inmunidad. Su historia —recuperación, quimioterapia, y una segunda infección devastadora— recuerda que la vulnerabilidad no desaparece con la primera batalla contra el virus. En un mundo donde apenas se han documentado 25 casos de reinfección, este caso singular obliga a la ciencia a preguntarse cuánto tiempo dura la protección y quiénes quedan expuestos cuando el cuerpo ya no puede recordar al enemigo.
Una mujer holandesa de 89 años se convirtió en la primera persona en morir confirmadamente por una reinfección de COVID-19, un hito que sacude las certezas sobre la inmunidad al virus. Había sobrevivido la primera infección durante la ola inicial de la pandemia: cinco días hospitalizada, fiebre alta, tos persistente, y luego dos pruebas PCR negativas que le abrieron la puerta de regreso a casa. Sin embargo, padecía Macroglobulinemia de Waldenström, un raro cáncer de médula ósea que erosionaba silenciosamente sus defensas.
Dos meses después de recuperarse, retomó la quimioterapia. En cuestión de días, la fiebre regresó, seguida de tos y una dificultad respiratoria severa que la devolvió al hospital. Las pruebas confirmaron una segunda infección por COVID-19, pero las pruebas serológicas no detectaron anticuerpos de la primera infección: su sistema inmunológico había olvidado al virus por completo.
Su estado se deterioró con rapidez. Murió dos semanas después de su segunda hospitalización. La viróloga Marion Koopmans, quien sigue los casos de reinfección para la Universidad de Oxford, reconoció el papel del virus en su muerte, aunque subrayó que la paciente ya estaba gravemente enferma a causa del cáncer.
El caso enciende un debate urgente sobre la duración de la inmunidad natural y sus implicaciones para las vacunas. Koopmans advirtió que, si bien las reinfecciones siguen siendo excepcionales, es probable que aumenten con el tiempo, y fue directa sobre un límite fundamental: ningún virus respiratorio ha conferido jamás una protección de por vida. Lo que este caso revela con claridad es que quienes tienen el sistema inmunológico comprometido enfrentan un riesgo real incluso después de haber superado la enfermedad.
An 89-year-old Dutch woman has become the first confirmed death from COVID-19 reinfection, a grim milestone that raises urgent questions about how long immunity lasts and who remains vulnerable even after recovering from the virus.
The woman had survived her initial infection during the first wave of the pandemic. She developed the classic symptoms—high fever and a persistent cough—and spent five days in the hospital before being discharged. Two PCR tests came back negative after her symptoms cleared, and she was sent home to recover. But she carried a complication that would prove catastrophic: Waldenström macroglobulinemia, a rare form of bone marrow cancer that had been steadily weakening her immune system for months.
Two months after her recovery, the woman began a new round of chemotherapy. Within two days, fever returned. Then came the cough again, and a severe shortness of breath that forced her back into the hospital. This time, a PCR test showed she had contracted COVID-19 a second time. Yet when doctors ran serological tests to check for antibodies from her first infection, those came back negative—suggesting her immune system had lost its memory of the virus entirely.
Her condition deteriorated rapidly. Eight days into her second hospitalization, her health collapsed. She died two weeks later. Marion Koopmans, a virologist tracking reinfection cases for Oxford University, acknowledged the virus likely played a role in her death, but noted the woman was already gravely ill from her cancer. "She was very sick," Koopmans told local media.
The case arrives at a moment of deep uncertainty about COVID-19 immunity. Globally, only about 25 reinfection cases have been documented so far, making them extraordinarily rare. In most of those cases, the second infection produced milder symptoms than the first. But this death suggests that reinfection poses a genuine threat to people whose immune systems have been compromised—whether by cancer, chemotherapy, or other conditions that suppress the body's defenses.
Koopmans emphasized that reinfections remain exceptional events, though she expects more will emerge as the pandemic continues. The critical question, she suggested, is whether reinfection is unique to COVID-19 or a pattern seen with other respiratory viruses. The timing of this woman's second infection—just two months after her first—was unusually fast, which may have reflected her weakened immune state rather than a general pattern.
Scientists are still grappling with what these cases mean for vaccine development and the durability of natural immunity. The evidence suggests that antibodies produced after an initial infection can fade relatively quickly in some people, particularly those with compromised immune systems. Koopmans expressed cautious hope that most people who recover from COVID-19 will remain protected for an extended period, but she was clear about a hard truth: "This protection will not last a lifetime, because we have never seen that with any respiratory virus." The implications for long-term pandemic strategy remain uncertain.
Citazioni salienti
She was very sick, and the coronavirus likely played a role in her death, but her underlying cancer was already grave.— Marion Koopmans, virologist
This protection will not last a lifetime, because we have never seen that with any respiratory virus.— Marion Koopmans, virologist
Vuoi la storia completa?
Leggi l'originale su Diario Ojo ↗
Health & Medicine